Multi-step regulation of transcription kinetics explains the non-linear relation between RNA polymerase II density and mRNA expression in Dosage Compensation

Pouria Dasmeh^{1,2,3}

¹Departement de Biochimie, ²Centre Robert Cedergren en Bioinformatique et Génomique, Université de Montréal, 2900 Edouard-Montpetit, Montreal, Quebec H3T 1J4, Canada. ³Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA USA 02139.

Abstract

In heterogametic organisms, expression of unequal number of X chromosomes in males and females is balanced by a process called dosage compensation. In *Drosophila* and mammals, dosage compensation involves nearly two-fold up-regulation of the X chromosome mediated by dosage compensation complex (DCC). Experimental studies on the role of DCC on RNA polymerase II (Pol II) transcription in mammals disclosed a non-linear relationship between Pol II densities at different transcription steps and mRNA expression. An ~20-30% increase in Pol II densities corresponds to a rough 200% increase in mRNA expression and two-fold up-regulation. Here, using a simple kinetic model of Pol II transcription calibrated by *in vivo* measured rate constants of different transcription steps in mammalian cells, we demonstrate how this non-linearity can be explained by multi-step transcriptional regulation. Moreover, we show how multi-step enhancement of Pol II transcription can increase mRNA production while leaving Pol II densities unaffected. Our theoretical analysis not only recapitulates experimentally observed Pol II densities upon two-fold up-regulation but also points to a limitation of inferences based on Pol II profiles from chromatin immunoprecipitation sequencing (ChIP-seq) or global run-on assays.

36 **Body**

37
38 Unequal number of X chromosomes in males and females of several organisms
39 imposes a dosage problem on expression of X-linked genes. In the absence of a proper
40 regulatory mechanism, this disparity potentially leads to unequal expression of X-linked
41 genes and sex lethality. To overcome this challenge, a “dosage compensation”
42 mechanism is evolved to compensate the expression of X chromosomes¹⁻³. In
43 *Drosophila*, the one copy of X-chromosome in males is roughly transcribed by two-
44 fold to balance the expression of the two X chromosomes in females⁴⁻⁷. In mammals,
45 an X chromosome in females is primarily inactivated to balance the expression of X-
46 linked genes with males⁸⁻¹⁰. Moreover, mammalian X chromosome is further hyper-
47 transcribed in order to satisfy X-Autosome expression ratio^{11,12}.

48 Recent studies in *Drosophila* and mammals using chromatin
49 immunoprecipitation and global-run-on sequencing (i.e., ChIP-seq and GRO-seq) have
50 addressed the interference of dosage compensation with Pol II transcription at different
51 steps. In mouse embryonic stem cells (ES cells), dosage compensation is shown to
52 increase Pol II densities at initiation (i.e., phosphorylated Pol II at Serine 5, i.e., Pol
53 II-S5P) without significant changes in the elongated form of Pol II (i.e.,
54 phosphorylated Pol II at Serine 2 or Pol II-S2P)¹³. In another study of dosage
55 compensation in mouse female embryonic kidney fibroblasts, both Pol II-S5P and
56 PolII-S2P densities were found enhanced¹². In *Drosophila*, whether dosage
57 compensation facilitates Pol II progression across active X-linked genes¹⁴ or enhance
58 recruitment of Pol II to promoters¹⁵ has been controversial¹⁶⁻¹⁸.

59 From the above-mentioned experimental studies, one emerging pattern is a non-
60 linear relationship between Pol II densities at different steps of transcription and mRNA
61 expression level**Error! Bookmark not defined.** In *Drosophila*, Pol II tag density

over the bodies of X-linked genes compared to autosomal genes is shown to differ by a factor of $\sim 1.4^{14}$ with ~ 1.2 folds increase at promoters¹⁷. In the case of X chromosome up-regulation in mammals, Pol II at promoters and along the body of active genes was reported to be increased by ~ 1.3 and ~ 1.2 fold respectively¹². In both examples, mRNA levels are increased by $\sim$ two-fold upon hyper transcription. How does an $\sim 30\%$ increase in Pol II density gives rises to $\sim 200\%$ increase in mRNA production?

Here, we justify this non-linear relationship based on multi-step regulation of transcription machinery. Our assumption is that dosage compensation is achieved by proper alterations of different steps of Pol II transcription. We use the following kinetic framework for Pol II transcription (Figure 1A):

$$\frac{d[P_{pic}]}{dt} = -k_{ini}[P_{pic}] + k_{on}[P_{free}] - k_{off}[P_{pic}] \quad (1)$$

$$\frac{d[P_{ini}]}{dt} = k_{ini}[P_{pic}] - k_{esc}[P_{ini}] - k_{abor}[P_{ini}] \quad (2)$$

$$\frac{d[P_{eng}]}{dt} = k_{esc}[P_{ini}] - k_{term}[P_{eng}] \quad (3)$$

$$\frac{d[P_{free}]}{dt} = k_{abor}[P_{ini}] + k_{term}[P_{eng}] - k_{on}[P_{free}] + k_{off}[P_{pic}] \quad (4)$$

$$\frac{d[mRNA]}{dt} = k_{term}[P_{eng}] - k_{exp}[mRNA] \quad (5)$$

Equations 1-5 describe dynamics of Pol II at different transcriptional steps (i.e., in pre-initiation complex, P_{pic} , at initiation, P_{ini} , engaged to gene bodies, P_{eng} , and as free molecules, P_{free}) and mRNA molecules. In this framework, free Pol II molecules bind to and unbound from promoters with the rate constants k_{on} and k_{off} and proceed to initiation and elongation with the rate constants of k_{ini} and k_{esc} . In addition to termination described by the rate constant k_{term} , Pol II transcription is stopped by abortive initiation with the rate constant k_{abor} . We modeled mRNA production and clearance by the term $(k_{term}[P_{eng}] - k_{exp}[mRNA])$ simplifying splicing and mRNA export out of nucleus into one rate constant, k_{exp} .

At steady-states, the relation between steady state mRNA expression and Pol II abundance at different steps of transcription can be expressed as:

$$\frac{[mRNA]_{ss}}{[P_{eng}]_{ss}} = \frac{k_{term}}{k_{exp}} \quad (6)$$

$$\frac{[mRNA]_{ss}}{[P_{ini}]_{ss}} = \frac{k_{esc}}{k_{exp}} \quad (7)$$

$$\frac{[mRNA]_{ss}}{[P_{pic}]_{ss}} = \frac{k_{esc}}{k_{exp}} \left(\frac{k_{ini}}{k_{esc} + k_{abor}} \right) \quad (8)$$

The ratios of Pol II abundances at different steps upon up-regulation (denoted by an “Up” superscript) to the original system are written as:

$$P_{eng} \text{ fold change} \equiv \frac{[P_{eng}]_{ss}^{Up}}{[P_{eng}]_{ss}} = \frac{[mRNA]_{ss}^{Up}}{[mRNA]_{ss}} \times \frac{\left(\frac{k_{exp}}{k_{term}} \right)^{Up}}{\left(\frac{k_{exp}}{k_{term}} \right)} \quad (9)$$

$$P_{ini} \text{ fold change} \equiv \frac{[P_{ini}]_{ss}^{Up}}{[P_{ini}]_{ss}} = \frac{[mRNA]_{ss}^{Up}}{[mRNA]_{ss}} \times \frac{\left(\frac{k_{exp}}{k_{esc}} \right)^{Up}}{\left(\frac{k_{exp}}{k_{esc}} \right)} \quad (10)$$

$$P_{pic} \text{ fold change} \equiv \frac{[P_{pic}]_{ss}^{Up}}{[P_{pic}]_{ss}} = \frac{[mRNA]_{ss}^{Up}}{[mRNA]_{ss}} \times \frac{\left\{ \frac{k_{exp}(k_{esc} + k_{abor})}{k_{esc}k_{ini}} \right\}^{Up}}{\left\{ \frac{k_{exp}(k_{esc} + k_{abor})}{k_{esc}k_{ini}} \right\}} \quad (11)$$

From equations 9 to 11, any change in Pol II abundance is proportional to mRNA fold change (i.e., $\frac{[mRNA]_{ss}^{Up}}{[mRNA]_{ss}}$) scaled with the ratio of up-regulated rate constants

to the original ones (e.g., $\frac{\left(\frac{k_{exp}}{k_{term}} \right)^{Up}}{\left(\frac{k_{exp}}{k_{term}} \right)}$ in the case of P_{eng} fold change). To calculate the left

sides of equations 9-11 and to check whether we can reckon the experimentally observed increased Pol II density at promoters and along the gene bodies, we calculated values of new rate constants assuming two-fold up-regulation. Theoretically, up-regulation can be modeled by one-step (i.e., changing one rate constant), two-step or multi-step perturbation to the original transcription system defined by equations 1-5.

Once dosage compensation was achieved (i.e., $[mRNA]_{ss}^{Up} = 2 [mRNA]_{ss}$), the new rate constants were used to calculate the fold changes in Pol II density at different stages

106 of transcription using equations 9 to 11. We employed *in vivo* estimates of Pol II
107 transcription rate constants in mammalian cells (See Table S1 for parameters used in
108 the model)¹⁹ and for simplicity assumed no change in mRNA export rate upon dosage
109 compensation (i.e., $k_{exp}^{Up} = k_{exp}$).

110 Perturbing one transcription step to achieve two-fold mRNA production linearly
111 increases Pol II abundance in subsequent steps (See Table S2). For example, increasing
112 the rate of initiation (i.e., by increasing k_{ini}) results in increased densities of P_{ini} , and
113 P_{eng} . However, two-step perturbation of transcription machinery causes less than two-
114 folds increase in abundance of Pol II at any step which its production and clearance rate
115 are increased simultaneously (See Table S3 and Figures S1-S10 for details). Figure 1B
116 shows mRNA fold change as a function of k_{ini} and k_{esc} . The intersection of the plane
117 $\frac{[mRNA]_{ss}'}{[mRNA]_{ss}} = 2$ with 3D curve of mRNA fold change defines a dosage compensation
118 surface where combinations of k_{ini} and k_{esc} result in two-fold hyper transcription. From
119 the figure, mRNA production is doubled by increasing initiation and promoter-escape
120 rate by ~1.2 to 2 folds, simultaneously. However, as shown in Figure 1C, P_{ini} is clearly
121 enriched less than two fold when k_{ini} and k_{esc} are changed at the same time. Given the
122 original kinetic rate constants, ~30% increase in P_{ini} corresponds to two-fold mRNA
123 production. A similar situation holds for P_{eng} when k_{esc} and k_{term} are perturbed at the
124 same time (Figures 1D and 1E). An ~20% increase in Pol II abundance along the gene
125 bodies is associated with two-fold mRNA production.

126 Although perturbing initiation and promoter-escape rates gives rises to P_{ini} fold
127 changes in agreement with experimentally observed values, P_{eng} is increased by ~two-
128 fold (See Table S3 for Pol II abundance at gene bodies while k_{ini} and k_{esc} are perturbed).
129 We thus checked a three-step perturbation analysis and found a combination of k_{ini} , k_{esc}

130 and k_{term} that satisfies ~10% to 30% increase in P_{ini} and gene bodies upon dosage
131 compensation (See Table S4 and S5 for details).

132 Next, we asked whether multi-step regulation of transcription can account for
133 two-fold mRNA expression while P_{ini} is unaffected. In Figure 1F, red and blue 3D
134 curves show mRNA and P_{ini} fold changes as functions of k_{ini} and k_{esc} . The intersection
135 of mRNA 3D curve with the plane at fold change=2 defines a 2D curve for dosage
136 compensation which is projected on $k_{\text{ini}}-k_{\text{esc}}$ plane in Figure 1F. We also projected the
137 intersection of 3D P_{ini} levels with the plane at fold change=1 in blue. These two curves
138 crossed each other at $k_{\text{esc}}^{\text{Up}} \sim 2k_{\text{esc}}$ and $k_{\text{ini}}^{\text{Up}} \sim 1.2k_{\text{ini}}$ causing two-fold mRNA
139 production and insignificant changes in P_{ini} levels. This condition corresponds to an
140 expected ChIP profile in Figure 1G which is most likely misinterpreted as no change in
141 Pol II densities at initiation and a significant change in Pol II densities at elongation
142 steps, although both steps have been enhanced (schema in Figure 1H). In line with
143 previous studies on erroneous inferences from ChIP profiles²⁰ and inapplicability of
144 ChIP-seq and Gro-seq in study of Pol II turnover²¹, our study systematically shows the
145 limitation of these methods in addressing relevance of Pol II enrichment at different
146 transcription steps.

147 Taken these together, our theoretical approach suggests that Pol II transcription
148 is most likely regulated at multiple steps in dosage compensation. How is a multi-step
149 regulation modulated by DCC? There is compelling evidence that DCC proteins,
150 individually or in synergy, influence different transcription steps²². For example, in
151 mammals it is shown that MSL1 and MOF, two members of DCC complex, contribute
152 to enhanced densities of Pol II-S5P and therefore facilitates initiation¹³. In addition,
153 MOF as an acetyltransferase is responsible for H4K16ac, a histon modification which
154 decompacts nucleosomes and enhanced promoter-escape and transcriptional

155 elongation^{14,18}. As we showed in this work, enhancing initiation, promoter-escape and
 156 elongation rates suffice to explain the nonlinearity between Pol II levels and mRNA
 157 expression.

158 The changes in kinetic constants are essential in reproducing the patterns of Pol
 159 II transcriptional regulation as shown in this work. Two approaches can be used to
 160 measure and compare kinetic rate constants. First, fluorescence recovery after
 161 photobleaching (FRAP) experiments¹⁹ can be used to infer kinetic rate constants of Pol
 162 II transcription in selected X-linked and autosomal genes in *Drosophila* or in
 163 mammalian cells. Second, following the work by Kim and Marioni²³, kinetic rate
 164 constants can be inferred from RNA-seq data of Pol II transcription at individual steps.
 165 We anticipate future experiments to address these issues.

166

167 **Acknowledgement**

168 Author is grateful to professor Asifa Akhtar and Max Planck Society for providing a
 169 research fellowship in Max Planck Institute for Immunobiology and Epigenetics,
 170 Freiburg, Germany.

171

172

173

174

175

176

177

178

179

180

181

182 References

- 183 1. Meyer, B.J. X-Chromosome dosage compensation. (2005).
- 184 2. Akhtar, A. Dosage compensation: an intertwined world of RNA and
- 185 chromatin remodelling. *Current opinion in genetics & development* **13**, 161-
- 186 169 (2003).
- 187 3. Conrad, T. & Akhtar, A. Dosage compensation in *Drosophila melanogaster*:
- 188 epigenetic fine-tuning of chromosome-wide transcription. *Nature reviews.*
- 189 *Genetics* **13**, 123 (2012).
- 190 4. Prestel, M., Feller, C., Straub, T., Mitlöhner, H. & Becker, P.B. The activation
- 191 potential of MOF is constrained for dosage compensation. *Molecular cell* **38**,
- 192 815-826 (2010).
- 193 5. Hamada, F.N., Park, P.J., Gordadze, P.R. & Kuroda, M.I. Global regulation of
- 194 X chromosomal genes by the MSL complex in *Drosophila melanogaster*.
- 195 *Genes & development* **19**, 2289-2294 (2005).
- 196 6. Straub, T., Gilfillan, G.D., Maier, V.K. & Becker, P.B. The *Drosophila* MSL
- 197 complex activates the transcription of target genes. *Genes & development* **19**,
- 198 2284-2288 (2005).
- 199 7. Park, S.-W., Oh, H., Lin, Y.-R. & Park, Y. MSL cis-spreading from roX gene
- 200 up-regulates the neighboring genes. *Biochemical and biophysical research*
- 201 *communications* **399**, 227-231 (2010).
- 202 8. Ohno, S., Kaplan, W. & Kinoshita, R. Formation of the sex chromatin by a
- 203 single X-chromosome in liver cells of *Rattus norvegicus*. *Experimental cell*
- 204 *research* **18**, 415-418 (1959).
- 205 9. Lyon, M.F. Gene action in the X-chromosome of the mouse (*Mus musculus*
- 206 *L.*). *nature* **190**, 372-373 (1961).
- 207 10. Gartler, S.M. & Riggs, A.D. Mammalian X-chromosome inactivation. *Annual*
- 208 *review of genetics* **17**, 155-190 (1983).
- 209 11. Disteche, C.M. Dosage compensation of the active X chromosome in
- 210 mammals. *Nature genetics* **38**, 47 (2006).
- 211 12. Yildirim, E., Sadreyev, R.I., Pinter, S.F. & Lee, J.T. X-chromosome
- 212 hyperactivation in mammals via nonlinear relationships between chromatin
- 213 states and transcription. *Nature structural & molecular biology* **19**, 56-61
- 214 (2012).
- 215 13. Deng, X. *et al.* Mammalian X upregulation is associated with enhanced
- 216 transcription initiation, RNA half-life, and MOF-mediated H4K16 acetylation.
- 217 *Developmental cell* **25**, 55-68 (2013).
- 218 14. Larschan, E. *et al.* X chromosome dosage compensation via enhanced
- 219 transcriptional elongation in *Drosophila*. *Nature* **471**, 115 (2011).
- 220 15. Conrad, T., Cavalli, F.M., Vaquerizas, J.M., Luscombe, N.M. & Akhtar, A.
- 221 *Drosophila* dosage compensation involves enhanced Pol II recruitment to male
- 222 X-linked promoters. *Science* **337**, 742-746 (2012).
- 223 16. Ferrari, F. *et al.* Comment on “*Drosophila* dosage compensation involves
- 224 enhanced Pol II recruitment to male X-linked promoters”. *Science (New York,*
- 225 *N.Y.)* **340**, 273-273 (2013).

- 226 17. Vaquerizas, J.M., Cavalli, F.M., Conrad, T., Akhtar, A. & Luscombe, N.M.
227 Response to comments on “Drosophila dosage compensation involves
228 enhanced Pol II recruitment to male X-Linked promoters”. *Science* **340**, 273-
229 273 (2013).
- 230 18. Ferrari, F. *et al.* “Jump start and gain” model for dosage compensation in
231 Drosophila based on direct sequencing of nascent transcripts. *Cell reports* **5**,
232 629-636 (2013).
- 233 19. Darzacq, X. *et al.* In vivo dynamics of RNA polymerase II transcription.
234 *Nature structural & molecular biology* **14**, 796-806 (2007).
- 235 20. Ehrensberger, A.H., Kelly, G.P. & Svejstrup, J.Q. Mechanistic interpretation
236 of promoter-proximal peaks and RNAPII density maps. *Cell* **154**, 713-715
237 (2013).
- 238 21. Henriques, T. *et al.* Stable pausing by RNA polymerase II provides an
239 opportunity to target and integrate regulatory signals. *Molecular cell* **52**, 517-
240 528 (2013).
- 241 22. Chlamydas, S. *et al.* Functional interplay between MSL1 and CDK7 controls
242 RNA polymerase II Ser5 phosphorylation. *Nature* **201**, 6 (2016).
- 243 23. Kim, J.K. & Marioni, J.C. Inferring the kinetics of stochastic gene expression
244 from single-cell RNA-sequencing data. *Genome biology* **14**, R7 (2013).
- 245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262 **Figure legends**

263 **Figure 1.** A) RNA polymerase II transcription can be perturbed at different steps
 264 (equations 1-6) to give two-fold mRNA production. In B) 3D curve for mRNA fold
 265 change is represented as a function of initiation, k_{ini} , and promoter-escape, k_{esc} , rate
 266 constants. C) 3D curve for P_{ini} fold changes as a function of k_{ini} and k_{esc} . D) mRNA fold
 267 change as a function of k_{esc} and elongation-termination rate constant, k_{term} . E) 3D curve
 268 for P_{eng} change as a function of k_{esc} and k_{term} . F) 3D curves for fold changes in mRNA
 269 (red) and P_{ini} (blue) are crossed with fold change=2 and fold change=1 planes
 270 respectively with their projection onto a 2D k_{ini} - k_{esc} plane shown in red and blue. G)
 271 ChIP profile for Pol II transcription can be misinterpreted as no significant change in
 272 P_{ini} and significant changes in P_{eng} while, as shown schematically in H) both k_{ini} and
 273 k_{esc} are increased at the same time.

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Supplementary information

Multi-step Transcriptional Regulation Explains Non-linear Relation between RNA polymerase II transcription and mRNA expression in Dosage Compensation

Pouria Dasmeh^{1,2,3}

¹Departement de Biochimie, ²Centre Robert Cedergren en Bioinformatique et Génomique, Université de Montréal, 2900 Edouard-Montpetit, Montreal, Quebec H3T 1J4, Canada. ³Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA USA 02139.

Table S1. Kinetic constants used in the kinetic model for POL-II transcription.

Parameter	Symbol	Value
Promoter binding constant	k_{on}	0.003 (s ⁻¹) ^a
Promoter dissociation constant	k_{off}	0.145 (s ⁻¹) ^b
Initiation constant	k_{ini}	0.0216 (s ⁻¹) ^b
Promoter escape constant	k_{esc}	0.00159 (s ⁻¹) ^b
Abortive initiation constant	k_{abor}	0.0176 (s ⁻¹) ^b
Termination constant	k_{term}	0.0016 (s ⁻¹) ^b

a: Taken from¹, b: Taken from²

Table S2. The fold change of POL-II at promoters. initiation and engaged phase in dosage

compensated genes ($1.8 < mRNA \text{ fold change} < 2.2$) caused by relative changes in each kinetic constant

Kinetic constant	P_{prom} fold change	P_{ini} fold change	P_{eng} fold change
k_{on}	1.86	1.86	1.86
k_{off}	1.98	1.98	1.99
k_{ini}	0.82	1.96	1.97

k_{esc}	0.99	0.895	1.98
k_{abor}	0.96	2.13	2.07
k_{term}	1.01	1.01	0.18

Table S3. Results of the fold change of POL-II at promoters. initiation and engaged phase in dosage compensated genes (X-chromosome) when $1.8 < mRNA \text{ fold change} < 2.2$.

Kinetic constants	P_{prom} fold change	P_{ini} fold change	P_{eng} fold change
(k _{on} .k _{off})	1.8897 ± 0.0553	1.8901 ± 0.0551	1.8935 ± 0.0553
(k _{on} .k _{ini})	1.3522 ± 0.3056	1.8699 ± 0.0560	1.8736 ± 0.0564
(k _{on} .k _{abor})	1.3272 ± 0.4825	1.9535 ± 0.1079	1.9484 ± 0.0942
(k _{on} .k _{esc})	1.4071 ± 0.2729	1.3630 ± 0.2978	1.8853 ± 0.0620
(k _{on} .k _{term})	1.7088 ± 0.1113	1.7090 ± 0.1117	1.2911 ± 0.3626
(k _{off} .k _{ini})	1.6044 ± 0.7755	1.8754 ± 0.0594	1.8787 ± 0.0597
(k _{off} .k _{abor})	1.5792 ± 0.8715	1.9416 ± 0.0857	1.9385 ± 0.0791
(k _{off} .k _{esc})	1.5663 ± 0.6070	1.5378 ± 0.6631	1.8776 ± 0.0612
(k _{off} .k _{term})	1.9427 ± 0.5479	1.9436 ± 0.5502	2.1496 ± 1.9574
(k _{ini} .k _{abor})	0.9239 ± 0.0546	1.9479 ± 0.1303	1.9424 ± 0.1145
(k _{ini} .k _{esc})	0.9234 ± 0.0382	1.2905 ± 0.2435	1.8928 ± 0.0628
(k _{ini} .k _{term})	0.8893 ± 0.0149	1.6436 ± 0.0662	1.0716 ± 0.1921
(k _{abor} .k _{esc})	0.9699 ± 0.0199	1.6007 ± 0.9280	1.9138 ± 0.0656
(k _{abor} .k _{term})	0.9601 ± 0.0393	1.9707 ± 0.4837	2.0232 ± 1.5044
(k _{esc} .k _{term})	0.9978 ± 0.0057	0.9345 ± 0.0148	1.1898 ± 0.3057

Table S4. Different combinations of rate constants which satisfy $1.1 < P_{\text{eng}} \text{ fold change} < 1.3$. $1.1 < P_{\text{ini}}$ fold change < 1.3 and $1.1 < P_{\text{prom}}$ fold change < 1.3 .

k_{ini} (fold increase)	k_{esc} (fold increase)	k_{term} (fold increase)
1.2	1.5	1.3
1.2	1.5	1.4
1.2	1.5	1.5
1.2	1.6	1.3
1.2	1.6	1.4
1.2	1.6	1.5
1.2	1.6	1.6
1.3	1.4	1.3
1.3	1.4	1.4
1.3	1.4	1.5
1.3	1.5	1.4
1.3	1.5	1.5
1.3	1.5	1.6
1.3	1.6	1.4
1.3	1.6	1.5
1.3	1.6	1.6
1.4	1.3	1.3
1.4	1.3	1.4
1.4	1.3	1.5
1.4	1.4	1.4
1.4	1.4	1.5
1.4	1.4	1.6

1.4	1.5	1.4
1.4	1.5	1.5
1.4	1.5	1.6
1.5	1.2	1.4
1.5	1.2	1.5
1.5	1.3	1.3
1.5	1.3	1.4
1.5	1.3	1.5
1.5	1.3	1.6
1.5	1.4	1.4
1.5	1.4	1.5
1.5	1.4	1.6

The correlations between the kinetic constants and POL-II abundance at different stages of transcription are shown in Table S5.

Table S5. The correlations (+) or anticorrelation (-) between rate constants and POL-II abundance at different stages of transcription.

Parameter	P_{prom}	P_{ini}	$P_{\text{prom}}+P_{\text{ini}}$	P_{eng}
k_{on}	+	+	+	+
k_{off}	-	-	-	-
k_{ini}	-	+	+	+
k_{abor}	+	-	-	-
k_{esc}	-	-	-	+
k_{term}	+	+	+	-

In the following figures, the effect of increase or decrease in rate constants on mRNA production is quantified in terms of *mRNA ratio* defined as:

$$mRNA\ ratio = \frac{[mRNA](perturbed\ rate\ constants)}{[mRNA](original\ rate\ constants)} \quad (6)$$

Other abundance ratios defined in this work (e.g., $P_{prom}\ ratio$) are calculated similarly

$$(i.e., P_{prom}\ ratio = \frac{[P_p](perturbed\ rate\ constants)}{[P_p](original\ rate\ constants)}).$$

Figure S1. *mRNA* fold change as a function of varying k_{ini} and k_{esc} from one-tenth to two-fold of their original values (i.e., $k_{ini}=0.0216\ s^{-1}$ and $k_{esc}=0.00159\ s^{-1}$).

Figure S2. P_{prom} fold change as a function of varying k_{ini} and k_{esc} from one-tenth to two-fold of their original values (i.e., $k_{\text{ini}}=0.0216 \text{ s}^{-1}$ and $k_{\text{esc}}=0.00159 \text{ s}^{-1}$).

Figure S3. P_{ini} fold change as a function of varying k_{ini} and k_{esc} from one-tenth to two-fold of their original values (i.e., $k_{\text{ini}}=0.0216 \text{ s}^{-1}$ and $k_{\text{esc}}=0.00159 \text{ s}^{-1}$).

Figure S4. P_{eng} fold change as a function of varying k_{ini} and k_{esc} from one-tenth to two-fold of their original values (i.e., $k_{ini}=0.0216 \text{ s}^{-1}$ and $k_{esc}=0.00159 \text{ s}^{-1}$).

Figure S5. mRNA fold change as a function of varying k_{on} and k_{off} from one-tenth to two-fold of their original values (i.e., $k_{on}=0.0216 \text{ s}^{-1}$ and $k_{off}=0.00159 \text{ s}^{-1}$).

Figure S5. P_{prom} fold change as a function of varying k_{on} and k_{off} from one-tenth to two-fold of their original values (i.e., $k_{\text{on}}=0.0216 \text{ s}^{-1}$ and $k_{\text{off}}=0.00159 \text{ s}^{-1}$).

Figure S6. P_{ini} fold change as a function of varying k_{on} and k_{off} from one-tenth to two-fold of their original values (i.e., $k_{\text{on}}=0.0216 \text{ s}^{-1}$ and $k_{\text{off}}=0.00159 \text{ s}^{-1}$).

Figure S6. P_{eng} fold change as a function of varying k_{on} and k_{off} from one-tenth to two-fold of their original values (i.e., $k_{\text{on}}=0.0216 \text{ s}^{-1}$ and $k_{\text{off}}=0.00159 \text{ s}^{-1}$).

Figure S7. mRNA fold change as a function of varying k_{abor} and k_{term} from one-tenth to two-fold of their original values (i.e., $k_{\text{abor}}=0.0170 \text{ s}^{-1}$ and $k_{\text{term}}=0.0016 \text{ s}^{-1}$).

Figure S8. P_{prom} fold change as a function of varying k_{abor} and k_{term} from one-tenth to two-fold of their original values (i.e., $k_{\text{abor}}=0.0170 \text{ s}^{-1}$ and $k_{\text{term}}=0.0016 \text{ s}^{-1}$).

Figure S9. P_{ini} fold change as a function of varying k_{abor} and k_{term} from one-tenth to two-fold of their original values (i.e., $k_{\text{abor}}=0.0170 \text{ s}^{-1}$ and $k_{\text{term}}=0.0016 \text{ s}^{-1}$).

Figure S10. P_{eng} fold change as a function of varying k_{abor} and k_{term} from one-tenth to two-fold of their original values (i.e., $k_{abor}=0.0170 \text{ s}^{-1}$ and $k_{term}=0.0016 \text{ s}^{-1}$).

References

- ¹ Ferguson, Heather A., Jennifer F. Kugel, and James A. Goodrich. "Kinetic and mechanistic analysis of the RNA polymerase II transcription reaction at the human interleukin-2 promoter." *Journal of molecular biology* 314.5 (2001): 993-1006.
- ² Darzacq, Xavier, et al. "In vivo dynamics of RNA polymerase II transcription." *Nature structural & molecular biology* 14.9 (2007): 796-806.